P3, N=730, Terminated, EMD Serono Research & Development Institute, Inc. | Trial completion date: Apr 2027 --> Sep 2024 | Active, not recruiting --> Terminated; Study has crossed the pre-defined futility boundary at the Interim Analysis.

P3, N=166, Terminated, EMD Serono Research & Development Institute, Inc. | Active, not recruiting --> Terminated; No major safety concerns were identified in XRAY VISION study, but Lack of evidence of efficacy of meaningful clinical benefit.

P3, N=19, Suspended, Groupe Oncologie Radiotherapie Tete et Cou | Trial primary completion date: Jul 2024 --> Oct 2024

P1, N=18, Terminated, EMD Serono Research & Development Institute, Inc. | Active, not recruiting --> Terminated; No major safety concerns were identified in HyperlynX study, but Lack of evidence of efficacy of meaningful clinical benefit.

Several Survivin inhibitors, including YM-155, Debio1143, EM1421, LQZ-7I, and TL32711, have emerged as potential anticancer drugs awaiting validation in clinical trials. Furthermore, Wi-AREAL treatment activated apoptosis signaling, as evidenced by reduced PARP-1 and Bcl-2 levels, increased procaspase-3, and elevated Cytochrome C. Additionally, treating cells with a nontoxic low concentration (0.01%) of Wi-AREAL inhibited migration and invasion, as well as EMT (epithelial-mesenchymal transition) signaling. By combining computational and experimental approaches, we demonstrate the potential of Wi-A and Wi-AREAL as natural inhibitors of Survivin, which may be helpful in cancer treatment.

P2, N=230, Suspended, European Organisation for Research and Treatment of Cancer - EORTC | Recruiting --> Suspended

P2, N=4, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=54 --> 4

An adoptive cell targeting delivery of TNFα combined with an IAP antagonist is a novel effective approach to treat breast cancer and could be expanded to treat other solid cancers. Unlike CAR-T cell, this novel adoptive cell is not activated to produce a wide variety of cytokines, except for additional overexpressed TNF, and thus could avoid the severe side effects such as cytokine release syndrome.

P1, N=12, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Not yet recruiting --> Recruiting

P2, N=0, Withdrawn, ECOG-ACRIN Cancer Research Group | N=180 --> 0 | Not yet recruiting --> Withdrawn

P1, N=18, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Recruiting --> Active, not recruiting | N=40 --> 18 | Trial completion date: Apr 2025 --> Aug 2024 | Trial primary completion date: Apr 2025 --> Aug 2024

P3, N=166, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Recruiting --> Active, not recruiting | N=700 --> 166 | Trial completion date: Dec 2030 --> Sep 2024 | Trial primary completion date: Oct 2027 --> Sep 2024

P3, N=19, Suspended, Groupe Oncologie Radiotherapie Tete et Cou | N=538 --> 19 | Recruiting --> Suspended

P1, N=12, Not yet recruiting, H. Lee Moffitt Cancer Center and Research Institute

P1, N=42, Active, not recruiting, University of Chicago | Not yet recruiting --> Active, not recruiting | Initiation date: Jan 2025 --> Jan 2024

P1, N=42, Not yet recruiting, University of Chicago | Initiation date: Jan 2024 --> Jan 2025

P1, N=40, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting

Xevinapant combined with pembrolizumab was well tolerated with no unexpected adverse events. However, anti-tumor activity was low.

P2, N=180, Not yet recruiting, ECOG-ACRIN Cancer Research Group | Initiation date: Jan 2024 --> Apr 2024

P1, N=229, Recruiting, BeiGene | N=168 --> 229

P1, N=42, Not yet recruiting, University of Chicago | Trial primary completion date: Nov 2025 --> Oct 2027

P2, N=54, Recruiting, Memorial Sloan Kettering Cancer Center

P2, N=230, Recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting --> Recruiting

P2, N=54, Recruiting, Memorial Sloan Kettering Cancer Center

P1, N=40, Not yet recruiting, EMD Serono Research & Development Institute, Inc. | Phase classification: P1b --> P1 | Initiation date: Oct 2023 --> Jan 2024

P1, N=42, Not yet recruiting, University of Chicago

P2, N=180, Not yet recruiting, ECOG-ACRIN Cancer Research Group

P1, N=168, Recruiting, BeiGene | Trial completion date: Jul 2027 --> Nov 2026 | Trial primary completion date: Jan 2027 --> Dec 2025

Exposure-response relationships were not discernible for 12 of 13 evaluated safety endpoints, incidence of dose reductions, and time to first dose reduction. Quantitative integration of all available data, including model-derived target inhibition profiles, positive exposure-efficacy relationships, and lack of discernible exposure-safety relationships for most safety endpoints, supports selection of xevinapant 200 mg/day on days 1-14 of a 3-week cycle as the RP3D, allowing for successive dose reductions to 150 and 100 mg/day to manage adverse events.

Obtained biocompatible D@AgNP are stable over six months at room temperature and demonstrated absorbance peak at 406 nm...TEM finding shows that D@AgNP are mostly localized at vesicles such as the endosomes, lysosomes and mitochondria. It is anticipated that the introduced new method serves as the cornerstone for improving the generation of biocompatible hydrophilic carbohydrate-based anticancer drugs.

IAP antagonists have shown great promise for head and neck cancer, especially in combination with radiation therapy. Here, we review recent preclinical and clinical studies on the use of these novel targeted agents for head and neck cancer.

A phase 3 study, named TrilynX, in a larger group of people, is currently taking place to confirm the results of this study. Clinical Trial Registration: NCT02022098 (Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial) (ClinicalTrials.gov).

ED treat-and-release encounters are common after major gastrointestinal operations, making up nearly half of postdischarge ED encounters. The reasons for ED treat-and-release encounters differ from those for ED encounters with readmissions.

P3, N=538, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou

Xevinapant appears to be a potent new drug for HNSCC therapy, especially in combination with IR. IAP levels could be an indicator for impaired DNA damage repair and increased susceptibility to cellular stress.

No clear evidence to support the association between cholecystectomy and an increased risk of colorectal cancer. For patients with valid indications, timely cholecystectomy could be performed without the risk of colorectal cancer.

Radiotherapy alone for nasopharyngeal carcinoma with an intermediate-risk profile was found to be noninferior to chemoradiotherapy with cisplatin while improving tolerability...In the HNSCC-15-132 trial, sequential application of the PD‑1 inhibitor pembrolizumab to chemoradiotherapy was not significantly, but numerically superior to concomitant application...In addition, new 5‑year overall survival data from the phase II trial of chemoradiotherapy in combination with the inhibitor of apoptosis proteins (IAP) antagonist xevinapant versus placebo were presented. The xevinapant group continued to demonstrate a significant survival advantage and a sustained response to treatment.

Our study strongly suggests that SH3PXD2B is a carcinogenic molecule that can be used as a biomarker for GC detection, prognosis, treatment design, and follow-up.

P1/2, N=78, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

BGB-24714 effectively inhibited cIAP1 by inducing its degradation in MDA-MB-231 cells, with an EC50 of 2.5 nM. BGB-24714 also potently antagonized the inhibitory interaction of XIAP with caspase-9 and induced caspase-9 autoactivation in MDA-MB-231 cells, with an EC50 of 23 nM. In a total of 25 breast cancer cell lines treated with TNFα, BGB-24714 potently inhibited the in vitro proliferation of 5 breast cancer cells with EC50 < 100 nM.